Novo Nordisk A/S (NVO)
| Market Cap | 179.61B |
| Revenue (ttm) | 20.79B |
| Net Income (ttm) | 7.10B |
| Shares Out | 2.29B |
| EPS (ttm) | 3.02 |
| PE Ratio | 33.85 |
| Forward PE | 29.76 |
| Dividend | $1.47 (1.44%) |
| Ex-Dividend Date | Aug 16, 2021 |
| Volume | 524,031 |
| Open | 102.22 |
| Previous Close | 100.87 |
| Day's Range | 101.87 - 102.53 |
| 52-Week Range | 61.99 - 107.24 |
| Beta | 0.27 |
| Analysts | Hold |
| Price Target | 72.31 (-29.2%) |
| Est. Earnings Date | Nov 3, 2021 |
About NVO
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration a...
Financial Performance
In 2020, NVO's revenue was 126.95 billion, an increase of 4.04% compared to the previous year's 122.02 billion. Earnings were 42.14 billion, an increase of 8.18%.
Financial numbers in millions DKKFinancial StatementsAnalyst Forecast
According to 3 analysts, the average rating for NVO stock is "Hold." The 12-month stock price forecast is 72.31, which is a decrease of -29.18% from the latest price.
News
Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme
The 10 Richest People on Wall Street and How to Invest in Them
Knowing what stocks the richest people on Wall Street currently own could help you find potential winners for your portfolio. The post The 10 Richest People on Wall Street and How to Invest in Them appe...
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
2 Top Healthcare Stocks That Could Boost Your Portfolio in September (and Beyond)
These two companies have outperformed the market in the past year, and they are likely to continue doing so.
Analysts Differ Most About Potential for Novo's Weight-Loss Drug
Novo Nordisk AS's ( NVO , Financial) weight-loss drug is biopharma's most controversial blockbuster, according to a report from Evaluate Pharma. The highest and lowest forecasts for the Danish company's...
Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On 'Unacceptably High' Insulin Prices
House Energy & Commerce Committee leaders sent three letters to execs at Eli Lilly And Co (NYSE: LLY), Sanofi SA (NASDAQ: SNY), and Novo Nordisk A/S (NYSE: NVO), raising concerns that despite their supp...
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
3 Low-Risk Stocks for Conservative Investors
Protecting capital can be just as important as growing it.
Novo Nordisk CEO on product pricing: Our numbers are 'declining year-on-year'
Novo Nordisk CEO Lars Fruergaard Jørgensen joins Yahoo Finance's Julie Hyman to break down the company's strong second-quarter earnings, assess the pharmaceutical space amid the pandemic, and discuss th...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 10 August 2021
Bagsværd, Denmark, 11 August 202 1 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated person...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 9 August 2021
Bagsværd, Denmark, 10 August 202 1 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated person...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 5 August 2021
Bagsværd, Denmark, 9 August 202 1 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons...
Novo Nordisk's (NVO) Q2 Earnings and Sales Beat Estimates
Novo Nordisk (NVO) delivers better-than-expected results for Q2. Sales are aided by growth in Diabetes and Obesity Care owing to elevated GLP-1 revenues.
BofA Upgrades Novo Nordisk, Says Wegovy Obesity Drug Launch 'Far Exceeded' Expectations
Novo Nordisk A/S (NYSE:NVO) shares traded higher by 3.2% on Thursday morning after the insulin and diabetes care leader landed a major Wall Street upgrade. The Analyst: Bank of America analyst Sachin Ja...
Novo Nordisk Raises Forecasts on New Obesity Drug
Aug.05 -- Lars Fruergaard Jorgensen, Novo Nordisk chief executive officer, discusses first half earnings results. The Danish drug-maker raised its profit and sales forecasts for the year, reflecting hig...
Novo Nordisk Shares Are Trading Higher As GLP-1 Treatments Boost Q2 Topline, Bottom-line
Novo Nordisk A/S (NYSE: NVO) Q2 sales increased 10% Y/Y (17% at CER) to DKK 33.04 billion. Sales in International Operations increased 13% (17% CER) at DKK18.2 billion, and sales in North America Operat...
Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme
Why Is Novo Nordisk Buying a Rare-Disease Candidate?
The company is mainly known for its diabetes drugs but has some background in rare-disease drugs.
Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk
Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.
Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B
Novo Nordisk A/S (NYSE: NVO) will acquire Prothena Corporation plc's (NASDAQ: PRTA) and clinical stage antibody PRX004 and broader ATTR amyloidosis program. PRX004 is a Phase 2 ready immunotherapy desi...
Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion
Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp's experimental heart therapy, PRX004, in a deal that could be worth up to $1.23 billion, the companies said on Monday.